Market Place
Sourcing Support
Incyte`s Retifanlimab Extends PFS In Anal Carcinoma At ESMO 2024
14 Sep 2024 //
BUSINESSWIRE
Gilead to Present New Trodelvy® Data at IASLC 2024 World Lung Cancer Conference
05 Sep 2024 //
BUSINESSWIRE
Carboplatin UK Provides EU GMP Approved Chemotherapy Solutions
23 Aug 2024 //
PRESS RELEASE
CanariaBio Completes Enrollment For Oregovomab Phase 2 In Ovarian Cancer
23 Aug 2024 //
PR NEWSWIRE
FDA approves MSD’s KEYTRUDA for advanced endometrial cancer
18 Jun 2024 //
PRESS RELEASE
AZ Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer
17 Jun 2024 //
REUTERS
FDA approves J&J`s combination therapy for a type of lung cancer
02 Mar 2024 //
REUTERS
GSK`s cancer drug combination meets primary goal in late-stage trial
19 Dec 2023 //
PRESS RELEASE
Petrylak Provides Perspective on the Nationwide Cisplatin/Carboplatin Shortage
28 Aug 2023 //
ONCLIVE
Cisplatin, carboplatin shortages raise questions about impact on trials
18 Aug 2023 //
ENDPTS
FDA allows more imports of key cancer med from China`s Qilu
13 Jul 2023 //
FIERCE PHARMA
Debiopharm doses first patient in Phase I trial of cancer combo therapy
30 May 2023 //
CLINICAL TRIALS ARENA
Lantern Pharma Selects REPROCELL USA to & Support for the pH 2 Harmonic™
03 May 2023 //
BUSINESSWIRE
Qilu Pharma Latest Results of QL1604 plus Chemotherapy as First-Line Treatment
05 Dec 2022 //
BIOSPACE
GSK’s Jemperli RUBY PIII trial met its primary endpoint for endometrial cancer
02 Dec 2022 //
PRESS RELEASE
Merck`s KEYTRUDA & Chemotherapy Showed Sustained Survival Benefit
11 Sep 2022 //
BUSINESSWIRE
Lantern Pharma Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
BUSINESS WIRE
Merck Provides Update on Phase 3 KEYNOTE-921
03 Aug 2022 //
BUSINESSWIRE
Debiopharm Further Explores the Potential of Debio 0123 In Phase 1 Cancer Study
15 Dec 2021 //
PRNEWSWIRE
Seagen & Genmab Present Results From Tisotumab Vedotin Combination Therapy
20 Sep 2021 //
BUSINESSWIRE
IMFINZI+chemotherapy tripled patient OS at 3 years in PIII trial in ES-SCLC
18 Sep 2021 //
BUSINESSWIRE
Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types
08 Sep 2021 //
BUSINESSWIRE
Cantargia expands nadunolimab development in NSCLC
06 Sep 2021 //
PRNEWSWIRE
Merck & Co. says Keytruda, chemo combination meets OS endpoint in TNBC study
27 Jul 2021 //
PRESS RELEASE
Merck & Co. says Keytruda, chemo combination meets OS endpoint in TNBC study
27 Jul 2021 //
PRESS RELEASE
CytoDyn’s Positive Trial Data for Metastatic Triple-Negative Breast Cancer
12 Jul 2021 //
GLOBENEWSWIRE
ATEZOLIZUMAB WITH CARBOPLATIN AS IMMUNE INDUCTION SHOWS PROMISE
10 May 2021 //
ESMO
NKMax, Merck expand clinical collaboration to include phase I/IIa trial of SNK01
14 Apr 2021 //
PHARMABIZ
Tecentriq misses the mark in advanced ovarian cancer
14 Jul 2020 //
PMLIVE
NICE final guidance backs Pfizer`s Lorviqua
13 May 2020 //
PHARMA TIMES
Roche`s Tecentriq, chasing Merck`s Keytruda, nabs another FDA nod
05 Dec 2019 //
FIERCE PHARMA
Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA®
19 Oct 2019 //
BIOSPACE
Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy
16 Oct 2019 //
BUSINESSWIRE
Innovent Update on Results of IBI305 on Non-squamous Cell Lung Cancer
19 Sep 2019 //
BIOSPACE
Roche`s Tecentriq excels in another lung cancer study
13 Sep 2019 //
ENDPOINTSNEWS
Roche celebrates European approval of Tecentriq combo in first-line lung cancer
06 Sep 2019 //
PHARMAFILE
AstraZeneca’s Imfinzi tees up lung cancer fight with Roche
28 Jun 2019 //
FIERCE PHARMA
AstraZeneca Has Dazzled in Recent Cancer Trials, but Faces Stiff Competition
27 Jun 2019 //
BIOSPACE
Merck`s Keytruda gives BMS` Opdivo some company with small cell lung cancer nod
19 Jun 2019 //
FIERCE PHARMA
New lung cancer indication for Keytruda combo OK’d in EU
14 Mar 2019 //
PHARMA TIMES
FDA Expands Lilly`s pemetrexed Label with pembrolizumab & Pt Chemotherapy
31 Jan 2019 //
PR NEWSWIRE
FDA accepts Roche`s supplemental biologics license application for Tecentriq plus chemotherapy
16 Jan 2019 //
PRESS RELEASE
Roche`s lung cancer combo treatment wins FDA approval
07 Dec 2018 //
REUTERS
FDA approves Roche`s Tecentriq in combination with Avastin and chemotherapy
07 Dec 2018 //
GLOBENEWSWIRE
Genentech’s TECENTRIQ+Pemetrexed+Pt-Chemo Reduced Disease in Adv`d Lung Cancer
25 Sep 2018 //
BUSINESSWIRE
FDA Action Alert: Merck, Insmed and Antares Pharma
24 Sep 2018 //
FDA delays decision on Roche`s filing for Tecentriq, Avastin, chemo combination
12 Sep 2018 //
FIRST WORD PHARMA
BeiGene begins ph 3 trial of tislelizumab with chemo to treat advanced sNSCLC
12 Aug 2018 //
PHARMABIZ
Merck claims a win for Keytruda with interim OS data in H&NC
24 Jul 2018 //
ENDPTS
US priority review for Keytruda/chemo combo in first-line squamous NSCLC
03 Jul 2018 //
PHARMA TIMES
FDA Grants Priority Review to Merck’s Sup BLA for KEYTRUDA in NSCLC
02 Jul 2018 //
BUSINESSWIRE
US nod for Alimta/Keytruda lung cancer combo
07 Jun 2018 //
PHARMA TIMES
FDA Expands ALIMTA® Label to Include KEYTRUDA® (pembrolizumab) & Carboplatin
05 Jun 2018 //
PR NEWSWIRE
Two Roche Cancer Drugs Get Disappointing Results
04 Jun 2018 //
BIOSPACE
Roche drugs show limited benefit in lung, breast cancer trials
04 Jun 2018 //
REUTERS
Merck`s Keytruda boosts response in hard-to-treat lung cancer
17 May 2018 //
REUTERS
Roche reports +ve results from ph III IMpower150 study of Tecentriq & Avastin
17 May 2018 //
PHARMAIZ
Roche eyes September FDA verdict for triple NSCLC therapy
09 May 2018 //
PMLIVE
